文献速递血栓与止血

活检证实的MASLD患者静脉血栓栓塞发生率:全国队列研究

Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study.
PubMed 文献 · J Thromb Haemost · 2026-05-06

瑞典全国性匹配队列研究纳入11 073例活检确诊MASLD及50 078名对照,中位随访18.6年,VTE发生率为7.6 vs 3.4/1000人年,调整后HR 1.78(95%CI 1.65-1.91),门静脉血栓风险显著升高(aHR 3.40),且随MASLD严重程度递增。

要点

  • 每26例MASLD患者随访10年可额外发生1例VTE,绝对风险差3.9/1000人年。
  • 女性、基线合并癌症或代谢疾病者VTE风险更高,且风险随MASLD严重程度递增。

核心结论

  • 活检确诊的MASLD与VTE发生率升高相关,尤其是门静脉血栓。

研究设计与样本

  • 瑞典全国性、基于人群的匹配队列研究,纳入1965-2017年活检确诊MASLD患者,每例匹配至多5名一般人群对照,随访至2021年。

主要发现

  • 纳入11 073例MASLD和50 078名对照,中位随访18.6年,MASLD组VTE发生1291例,对照组4067例。
  • VTE发生率为7.6 vs 3.4/1000人年,aHR 1.78(95%CI 1.65-1.91),绝对风险差3.9/1000人年。
  • MASLD与癌症、住院及手术触发的VTE发生率升高相关,女性及基线合并癌症或代谢疾病者aHR更高。
  • 门静脉血栓风险显著升高(aHR 3.40,95%CI 2.93-3.95),且随MASLD严重程度递增(P = .003)。
  • 以兄弟姐妹为对照控制家族内混杂后结果相似。

临床怎么用

  • 对活检确诊MASLD患者应警惕VTE风险,尤其是门静脉血栓,需结合性别、癌症及代谢合并症进行风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The absolute and relative risk of venous thromboembolism (VTE) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely unexplored. We conducted a nationwide cohort study to explore this. OBJECTIVES: To calculate risk of developing VTE among MASLD. METHODS: This nationwide, population-based matched cohort study in Sweden included all individuals with biopsy-confirmed MASLD (1965-2017). MASLD was histologically classified into simple steatosis, metabolic dysfunction-associated steatohepatitis, noncirrhotic fibrosis, and cirrhosis. Each MASLD case was matched to up to 5 general population comparators. VTE events were identified using the Swedish National Patient Register up until 2021. RESULTS: We included 11 073 individuals with MASLD and 50 078 comparators. During a median follow-up of 18.6 years, incident VTE occurred in 1291 patients with MASLD and 4067 comparators. The incidence rate of VTE was higher in MASLD (7.6 vs 3.4 per 1000 person-years [PYs]), yielding an adjusted hazard ratio (aHR) of 1.78 (95% CI, 1.65-1.91). The absolute risk difference was 3.9 per 1000 PYs, equating to 1 extra VTE per 26 patients with MASLD over 10 years. MASLD was associated with a higher incidence of VTE triggered by cancer, hospitalization, and surgery. Higher aHRs were observed in women compared with men, and in patients with baseline cancer or metabolic disorders compared with those without. The risk of portal vein thrombosis was markedly elevated (aHR, 3.40; 95% CI, 2.93-3.95), increasing progressively with MASLD severity (P = .003). Findings were similar when siblings were used as comparators to account for intrafamilial confounding. CONCLUSION: Biopsy-confirmed MASLD was associated with a higher incidence of VTE, particularly portal vein thrombosis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Yuan S, Ebrahimi F, Forss A, et al. Incident venous thromboembolism in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study. J Thromb Haemost. 2026. PMID: 42102922. doi:10.1016/j.jtha.2026.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。